You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Apatinib

Showing 26 - 50 of 467
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Nanjing (Camrelizumab, TACE, Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Nanjing, Jiangsu, China
    Zhongda Hospital
Sep 8, 2022

Hepatocellular Carcinoma Trial (TACE+Camrelizumab+Apatinib mesylate, TACE)

Recruiting
  • Hepatocellular Carcinoma
  • TACE+Camrelizumab+Apatinib mesylate
  • TACE
  • Shanghai, Shanghai, China
    Zhongshan Hospital, Fudan University
Oct 17, 2022

Adrenocortical Carcinoma Trial (Camrelizumab)

Recruiting
  • Adrenocortical Carcinoma
  • Chengdu, Sichuan, China
    West China Hospital, Sichuan University
Dec 16, 2022

Ovarian Cancer Trial in Fuzhou (Fluzopari and apatinib)

Not yet recruiting
  • Ovarian Cancer
  • Fluzopari and apatinib
  • Fuzhou, Fujian, China
    Fujian Cancer Hospital
Oct 25, 2022

Hepatocellular Carcinoma Trial (Hepatectomy Combined With Camrelizumab and Apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • Hepatectomy Combined With Camrelizumab and Apatinib
  • Nanning, China
    Guangxi Medical University Cancer Hospital
Sep 4, 2022

Relapsed Ovarian Cancer Trial (Fluzoparib+Apatinib, Fluzoparib Monotherapy)

Not yet recruiting
  • Relapsed Ovarian Cancer
  • (no location specified)
Jul 27, 2022

Triple Negative Breast Cancer Trial in Beijing (SHR-1210 + Apatinib +Fluzoparib)

Completed
  • Triple Negative Breast Cancer
  • SHR-1210 + Apatinib +Fluzoparib
  • Beijing, Beijing, China
    Beijing Cancer Hosptial
Aug 9, 2022

Solid Tumor Trial in Henan (Camrelizumab combined with apatinib mesylate)

Recruiting
  • Solid Tumor
  • Camrelizumab combined with apatinib mesylate
  • Henan, China
    Henan Tumor Hospital
May 15, 2022

Metastatic Castration Resistant Prostate Cancer Trial in Shanghai (Fluzoparib, Enzalutamide OR abiraterone acetate With

Active, not recruiting
  • Metastatic Castration Resistant Prostate Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Sep 23, 2022

Intrahepatic Cholangiocarcinoma Trial in GuangZhou (HAIC Combined with Tislelizumab and Apatinib)

Recruiting
  • Intrahepatic Cholangiocarcinoma
  • HAIC Combined with Tislelizumab and Apatinib
  • GuangZhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Aug 4, 2022

Metastatic Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma Trial in Guangzhou (Camrelizumab,

Not yet recruiting
  • Metastatic Gastric Adenocarcinoma
  • Metastatic Gastroesophageal Junction Adenocarcinoma
  • Guangzhou, Guangdong, China
    The Sixth Affiliated hosipital, Sun Yat-Sen University
Apr 16, 2022

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ) Trial in Tianjin (Serplulimab+Paclitaxel+Apatinib,

Recruiting
  • Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Jul 5, 2023

Cancer Trial in Santa Monica (Apatinib, Nivolumab)

Active, not recruiting
  • Cancer
  • Santa Monica, California
    Sarcoma Oncology Research Center
May 19, 2022

Locally Advanced NSCLC Trial in Beijing (Camrelizumab, PD-1 mAb, Apatinib, VEGFR2 antibody)

Recruiting
  • Locally Advanced Non-Small Cell Lung Cancer
  • Camrelizumab, PD-1 monoclonal antibody
  • Apatinib, VEGFR2 antibody
  • Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Aug 15, 2022

Hepatocellular Carcinoma Trial in Guangzhou (camrelizumab& apatinib)

Recruiting
  • Hepatocellular Carcinoma
  • camrelizumab& apatinib
  • Guangzhou, Guangzhou, China
    Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sep 18, 2022

Gastric Cancer Trial in Seoul (Apatinib mesylate)

Completed
  • Gastric Cancer
  • Apatinib mesylate
  • Seoul, Songpa-gu, Korea, Republic of
    Asan medical center
Jul 20, 2022

Stage III Hepatocellular Cancer (CNLC Staging) Trial in Guangzhou (mFOLFOX7+Camrelizumab+Apatinib)

Recruiting
  • Stage III Hepatocellular Cancer (CNLC Staging)
  • Guangzhou, Guangdong, China
    Sun Yat-sen Memorial Hospital of Sun Yat-sen University
Jun 6, 2022

Camrelizumab Combined With Apatinib Mesylate in Unresectable

Recruiting
  • Hepatocellular Carcinoma
    • Fuzhou, Fujian, China
      Mengchao Hepatobiliary Hospital, Fujian Medical University
    Aug 24, 2022

    Triple Negative Breast Cancer Trial in Chengdu (Camrelizumab, Apatinib, Nab-paclitaxel)

    Not yet recruiting
    • Triple Negative Breast Cancer
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Jul 6, 2022

    Head and Neck Squamous Cell Carcinoma Trial in Shanghai (Apatinib Mesylate Tablets, Tegafur Gimeracil Oteracil Potassium

    Completed
    • Head and Neck Squamous Cell Carcinoma
    • Apatinib Mesylate Tablets
    • Tegafur Gimeracil Oteracil Potassium Capsules
    • Shanghai, Shanghai, China
      Shanghai ninth people's hospital
    Jul 20, 2022

    Thyroid Cancer Trial in Peking (Apatinib)

    Completed
    • Thyroid Cancer
    • Apatinib
    • Peking, China
      Peking Union Medical College Hospital
    Jan 18, 2022

    C-staged Hepatocellular Carcinoma in BCLC Classification Trial in Guangzhou, Guanzhou, Changsha (Hepatic Arterial Infusion

    Recruiting
    • C-staged Hepatocellular Carcinoma in BCLC Classification
    • Hepatic Arterial Infusion combined with Apatinib and Camrelizumab
    • Apatinib combined with Camrelizumab
    • Guangzhou, Guangdong, China
    • +4 more
    Jun 15, 2022

    Breast Cancer, Triple-Negative Breast Cancer Trial in Guangzhou, Nanjing, Shanghai (Anti-PD-1 mAb, VEGFR2 Tyrosine Kinase

    Recruiting
    • Breast Cancer
    • Triple-Negative Breast Cancer
    • Anti-PD-1 monoclonal antibody
    • VEGFR2 Tyrosine Kinase Inhibitor
    • Guangzhou, Guangdong, China
    • +2 more
    Sep 24, 2022

    Hepatocellular Carcinoma Trial in Guangzhou (FOLFOX-HAIC, Camrelizumab, Apatinib)

    Recruiting
    • Hepatocellular Carcinoma
    • FOLFOX-HAIC
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center Sun Yat-sen University
    Jan 19, 2022

    Gastric Cancer Trial in Shanghai (Apatinib)

    Completed
    • Gastric Cancer
    • Apatinib
    • Shanghai, Shanghai, China
      Shanghai 6th People's Hospital
    Feb 24, 2022